Featured Research

from universities, journals, and other organizations

Promising Possibility For Treatment Of Esophageal Carcinoma

Date:
September 24, 2008
Source:
World Journal of Gastroenterology
Summary:
Lithium, an inhibitor of glycogen synthase kinase 3 beta (GSK-3 beta ) activity, has been linked to reduced tumor incidence. A research group in China investigated the effect of lithium on proliferation of esophageal cancer cells and its preliminary mechanisms, and results demonstrate a growth-inhibitory role of lithium in Eca-109 cells by the inhibition of GSK-3 beta and reduction of cyclin B1 expression, which provides the treatment for the esophageal squamous cell carcinoma with lithium.

Recent work demonstrates that GSK-3 beta is involved in the process of tumorigenesis, and inhibition of the expression and activity of GSK-3 beta attenuates cell proliferation and causes apoptosis in colorectal, pancreatic and ovarian cancer cells.

Lithium is an existing drug for psychiatric diseases and its uptake has been linked to reduced tumor incidence compared to the general population, furthermore, lithium has been shown to be a specific and noncompetitive inhibitor of GSK-3 beta activity in vitro and in vivo.

Recent researches have proved that lithium could promote or inhibit cell cycle transition and proliferation of certain primary cultures or cell lines by inhibiting GSK-3 beta , depending on the cell type. However, whether lithium influences the growth and proliferation of esophageal cancer cells remains unknown to date.

A new research article demonstrates for the first time that lithium inhibited the proliferation of esophageal squamous cell carcinoma cells (Eca-109), which was mainly mediated by the inhibition of GSK-3 beta and reduction of cyclin B1 expression.

The authors demonstrated for the first time that lithium inhibited the proliferation of Eca-109 estimated by MTT assay and induce G2/M cell cycle arrest, which was mainly mediated by the inhibition of GSK-3beta and reduction of cyclin B1 expression. Lithium is an existing drug for psychiatric diseases and its uptake has been linked to reduced tumor incidence compared to the general population. Since the major target of lithium action has been shown to be GSK-3beta, the purpose of this study is reasonable and results are clearly demonstrated. Although further studies are required, this study indicates the novel possibility for the treatment of the esophageal squamous cell carcinoma with lithium cloride.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wang et al. Lithium inhibits proliferation of human esophageal cancer cell line Eca-109 by inducing a G2/M cell cycle arrest. World Journal of Gastroenterology, 2008; 14 (25): 3982 DOI: 10.3748/wjg.14.3982

Cite This Page:

World Journal of Gastroenterology. "Promising Possibility For Treatment Of Esophageal Carcinoma." ScienceDaily. ScienceDaily, 24 September 2008. <www.sciencedaily.com/releases/2008/09/080924111149.htm>.
World Journal of Gastroenterology. (2008, September 24). Promising Possibility For Treatment Of Esophageal Carcinoma. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/09/080924111149.htm
World Journal of Gastroenterology. "Promising Possibility For Treatment Of Esophageal Carcinoma." ScienceDaily. www.sciencedaily.com/releases/2008/09/080924111149.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins